Analysis of fibrinolytic proteins in relation to DNA ploidy in prostate cancer.
The tissue concentrations of urokinase-type plasminogen activator (u-PA), urokinase-type plasminogen activator receptor (u-PAR), plasminogen activator inhibitor type 1 (PAI-1) and tissue-type plasminogen activator (t-PA) were investigated by an ELISA technique in normal and malignant samples of the prostate from 24 patients undergoing radical prostatectomy for organ-confined prostate cancer. The median concentration of u-PA was significantly higher in cancerous than in normal prostate tissue (p = 0.006). No significant increase of u-PAR, PAI-1 and t-PA was found in cancer tissue in comparison with the benign samples (p > 0.05). Assessment of the relationship between fibrinolytic proteins and DNA ploidy revealed an increased u-PA, u-PAR and PAI-1 in diploid prostate cancer as compared with the normal controls. However, in aneuploid cancer u-PA remained high but u-PAR and PAI-1 were decreased. This led to a higher local concentration of u-PA in aneuploid samples than in normal prostate and in diploid prostate cancer. No alteration of median t-PA was found in benign prostate or in diploid or aneuploid prostate cancer. The altered expression of u-PA, u-PAR and PAI-1 in diploid and aneuploid prostate cancer suggests a possible role of fibrinolytic proteins in the different biologic behavior of tumors, and may be one explanation for the higher metastatic potential of aneuploid tumors.
Plas
E
E
Department of Urology and Ludwig Boltzmann Institute for Urology and Andrology, Lainz Hospital Vienna, Austria.
Carroll
V A
VA
Jilch
R
R
Mihaly
J
J
Vesely
M
M
Ulrich
W
W
Pflüger
H
H
Binder
B R
BR
D000368:Aged; D004247:DNA / Q000235:genetics; D004273:DNA, Neoplasm / Q000235:genetics; D004797:Enzyme-Linked Immunosorbent Assay; D005342:Fibrinolysis; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D017395:Plasminogen Activator Inhibitor 1 / Q000032:analysis*; D011003:Ploidies; D011467:Prostate / Q000737:chemistry / Q000378:metabolism*; D011471:Prostatic Neoplasms / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism* / Q000473:pathology; D011956:Receptors, Cell Surface / Q000032:analysis*; D055293:Receptors, Urokinase Plasminogen Activator; D010959:Tissue Plasminogen Activator / Q000032:analysis*; D014568:Urokinase-Type Plasminogen Activator / Q000032:analysis*
D004273:DNA, Neoplasm; C524898:PLAUR protein, human; D017395:Plasminogen Activator Inhibitor 1; D011956:Receptors, Cell Surface; D055293:Receptors, Urokinase Plasminogen Activator; D004247:DNA; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator